Interleukin 23 inhibition associates with lower incidence of cardiovascular risk factor type diseases compared with biologic-naïve patients with psoriasis: A retrospective cohort study - 14/11/24
Doi : 10.1016/j.jaad.2024.09.063
Ana Ormaza Vera, MD a, Chunghwan Ro, BS a, Waleed Adawi, MD, MS a, Alexander Yap, PharmD, MSc b, Abby S. Van Voorhees, MD a, Clinton W. Enos, MD, MS a, ⁎ 
a Department of Dermatology, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominium University, Norfolk, Virginia
b Department of Trial Design & Optimization, TriNetX, LLC, Cambridge, Massachusetts
∗Correspondence to: Clinton W. Enos, MD, MS, Department of Dermatology, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominium University, 721 Fairfax Avenue, Suite 200, Andrews Hall, Norfolk, VA 23507Department of DermatologyEastern Virginia Medical SchoolMacon & Joan Brock Virginia Health Sciences at Old Dominium University721 Fairfax AvenueSuite 200Andrews HallNorfolkVA23507
En prensa. Pruebas corregidas por el autor.
Disponible en línea desde el Thursday 14 November 2024
This article has been published in an issue click here to access
This article has been published in an issue click here to access
Key words : biologics, cardiovascular risk, diabetes, dyslipidemia, hypertension, incidence, inflammatory, MACEs, psoriasis, psoriasis therapy
| Funding sources: None. |
|
| IRB approval status: Exempt. |
© 2024
Publicado por Elsevier Masson SAS.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?